Agenda |
||
| 7:00—8:00am | Registration and Breakfast | |
| 8:00—8:05am | Opening Comments | Joan H. Schiller |
| 8:05—9:20am | New Avenues for Lung Cancer Screening | Moderator: James R. Jett |
| The Potential of Airway-Based Biomarkers for Lung Cancer Screening | Simon Spivack | |
| Opportunities Arising From the NLST | Denise Aberle | |
| Who Should Be Screened? Understanding and Evaluating Risk | Stephen Lam | |
| Panel Discussion | ||
| 9:20—10:45am | Novel Therapeutic Targets | Moderator: Pasi Jänne |
| LKB1-STRAD Interactions and Lung Cancer Invasion: Opportunities for Therapy | Adam Marcus | |
| PARP Inhibitors: Hope or Hype? | Suresh Ramalingam | |
| Immunotherapy for the Treatment of Non-Small Cell Lung Cancer | Julie Brahmer | |
| Targeting ALK in Lung Cancer | Pasi Jänne | |
| Panel Discussion | ||
| 10:45—11:00am | Break | |
| 11:00—12:25pm | Implementing Personalized Medicine | Moderator: Fred Hirsch |
| The Promise and Peril of Understanding Biomarkers: Implications for Clinical Trial Design | Lucinda Billingham | |
| Validating Cancer Tests -- What Should Clinicians Know? | Karen Bijwaard | |
| Sex Differences in Genomic Arrays of Lung Tumors | Anil Potti | |
| Effects of Estrogen on Nicotinic Receptor-Mediated Responses to the Nicotine Derivative NNK | Hildegard Schuller | |
| Panel Discussion | ||
| 12:25—12:30pm | Closing Remarks/Meeting Adjourn | Joan H. Schiller |
